Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201
Fig 5
T1-116C exhibits no toxicity in human HLA-A2 transgenic HHD mice.
Female HHD mice (6–8 weeks old) were injected intraperitoneally with T1-116CV1 (n = 5) or a control mAb (n = 5) at 20mg/kg, twice per week, for 8 weeks. Mice were monitored for signs of adverse effects throughout the course of treatment. (A) Monitoring of body weights (mean ± SEM). Mouse body weights were measured twice weekly. (B) Effect of antibody treatment on blood cell subsets. Antibodies against CD11b and Gr1 were used to identify the granulocytes, while antibodies against CD19 and CD3 were used to identify B and T lymphocytes respectively. The flow cytometry plots are representative of the results observed in each treatment group. No significant difference in the percentages of cells was observed between the T1-116CV1 and the control group. The bar graphs represent the mean ± SEM (n = 5). (C) Hematoxylin and eosin staining of organs showed no histological signs of toxicity. Representative images at 10X magnification are shown.